- Home
- TLF vs NOTV Comparison
TLF vs NOTV Comparison
Compare TLF & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLF
- NOTV
- Stock Information
- Founded
- TLF 1980
- NOTV 1974
- Country
- TLF United States
- NOTV United States
- Employees
- TLF N/A
- NOTV N/A
- Industry
- TLF Apparel
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- TLF Consumer Discretionary
- NOTV Health Care
- Exchange
- TLF Nasdaq
- NOTV Nasdaq
- Market Cap
- TLF N/A
- NOTV 62.5M
- IPO Year
- TLF N/A
- NOTV 1997
- Fundamental
- Price
- TLF $3.30
- NOTV $2.00
- Analyst Decision
- TLF
- NOTV Strong Buy
- Analyst Count
- TLF 0
- NOTV 1
- Target Price
- TLF N/A
- NOTV $5.00
- AVG Volume (30 Days)
- TLF 11.1K
- NOTV 512.6K
- Earning Date
- TLF 08-06-2025
- NOTV 08-07-2025
- Dividend Yield
- TLF 44.99%
- NOTV N/A
- EPS Growth
- TLF 241.69
- NOTV N/A
- EPS
- TLF 1.47
- NOTV N/A
- Revenue
- TLF $74,152,000.00
- NOTV $480,402,000.00
- Revenue This Year
- TLF N/A
- NOTV $4.99
- Revenue Next Year
- TLF N/A
- NOTV $5.39
- P/E Ratio
- TLF $2.24
- NOTV N/A
- Revenue Growth
- TLF N/A
- NOTV N/A
- 52 Week Low
- TLF $2.69
- NOTV $1.15
- 52 Week High
- TLF $5.48
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- TLF 61.00
- NOTV 49.04
- Support Level
- TLF $3.10
- NOTV $2.06
- Resistance Level
- TLF $3.42
- NOTV $2.30
- Average True Range (ATR)
- TLF 0.10
- NOTV 0.17
- MACD
- TLF 0.02
- NOTV 0.02
- Stochastic Oscillator
- TLF 67.93
- NOTV 70.31
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.